JP7005779B2 - 急性骨髄性白血病又は転移性乳癌の予防又は治療用薬剤学的組成物 - Google Patents

急性骨髄性白血病又は転移性乳癌の予防又は治療用薬剤学的組成物 Download PDF

Info

Publication number
JP7005779B2
JP7005779B2 JP2020543443A JP2020543443A JP7005779B2 JP 7005779 B2 JP7005779 B2 JP 7005779B2 JP 2020543443 A JP2020543443 A JP 2020543443A JP 2020543443 A JP2020543443 A JP 2020543443A JP 7005779 B2 JP7005779 B2 JP 7005779B2
Authority
JP
Japan
Prior art keywords
compound
imino
ethoxy
flt3
bindrinylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020543443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501208A (ja
JP2021501208A5 (enExample
Inventor
キム，ヨンチュル
チョン，ピョン－ファ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pelemed Co Ltd
Original Assignee
Pelemed Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pelemed Co Ltd filed Critical Pelemed Co Ltd
Publication of JP2021501208A publication Critical patent/JP2021501208A/ja
Publication of JP2021501208A5 publication Critical patent/JP2021501208A5/ja
Application granted granted Critical
Publication of JP7005779B2 publication Critical patent/JP7005779B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020543443A 2017-10-31 2018-10-30 急性骨髄性白血病又は転移性乳癌の予防又は治療用薬剤学的組成物 Active JP7005779B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0144142 2017-10-31
KR20170144142 2017-10-31
PCT/KR2018/013051 WO2019088677A1 (ko) 2017-10-31 2018-10-30 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물

Publications (3)

Publication Number Publication Date
JP2021501208A JP2021501208A (ja) 2021-01-14
JP2021501208A5 JP2021501208A5 (enExample) 2021-02-25
JP7005779B2 true JP7005779B2 (ja) 2022-02-10

Family

ID=66333236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543443A Active JP7005779B2 (ja) 2017-10-31 2018-10-30 急性骨髄性白血病又は転移性乳癌の予防又は治療用薬剤学的組成物

Country Status (12)

Country Link
US (1) US11370779B2 (enExample)
EP (1) EP3705474A4 (enExample)
JP (1) JP7005779B2 (enExample)
KR (1) KR102247795B1 (enExample)
CN (1) CN111542513A (enExample)
AU (1) AU2018358582B2 (enExample)
BR (1) BR112020008499A2 (enExample)
CA (1) CA3080900C (enExample)
MX (1) MX2020004374A (enExample)
PH (1) PH12020550491A1 (enExample)
RU (1) RU2763346C2 (enExample)
WO (1) WO2019088677A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020216661A1 (en) 2019-04-26 2020-10-29 Unilever Plc Hair conditioning composition
CN110305056A (zh) * 2019-05-22 2019-10-08 西北大学 靛玉红新衍生物及其药用用途
EP4010337A4 (en) * 2019-11-04 2023-08-23 CK Regeon Inc. COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING NEURODEGENERATIVE DISEASES AND/OR ASSOCIATED CLINICAL CONDITION
WO2021112626A1 (ko) * 2019-12-06 2021-06-10 주식회사 펠레메드 신규한 인디루빈 유도체 및 이의 용도
KR102443617B1 (ko) * 2019-12-06 2022-09-16 광주과학기술원 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물
KR20210106155A (ko) 2020-02-20 2021-08-30 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 페닐카르보노히드라조노일 디시아나이드 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
KR102325607B1 (ko) 2020-02-20 2021-11-12 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
KR102278176B1 (ko) 2020-02-20 2021-07-16 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조디옥솔 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
US20220079934A1 (en) * 2020-09-17 2022-03-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pain
KR102744517B1 (ko) * 2022-02-14 2024-12-19 주식회사 펠레메드 신규한 헤테로비시클릭 잔기를 갖는 인디루빈 유도체 및 이의 용도
WO2024181799A1 (ko) * 2023-02-28 2024-09-06 주식회사 씨케이리제온 신규한 인돌린 유도체 및 이의 용도

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541244A (ja) 1999-04-12 2002-12-03 ゲルハルト アイゼンブランド インジゴイドビスインドール誘導体
JP2007519713A (ja) 2004-01-27 2007-07-19 エニジェン カンパニー リミテッド ヒト癌細胞に対する抗癌性を有するインジルビン誘導体
JP2013518874A (ja) 2010-02-05 2013-05-23 エニジェン カンパニー．，リミテッド． 強力なサイクリン依存性キナーゼ阻害剤としてのインディルビン−３’−オキシム誘導体
US20140275168A1 (en) 2013-03-14 2014-09-18 City Of Hope Indirubin derivatives, and uses thereof
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins
JP2016514160A (ja) 2013-03-14 2016-05-19 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ ５−ブロモ−インジルビン
US20160243077A1 (en) 2012-03-23 2016-08-25 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US8552053B2 (en) * 2005-12-23 2013-10-08 Centre National De La Recherche Scientifique 7-substituted indirubin-3′oximes and their applications
ATE529402T1 (de) 2008-08-01 2011-11-15 Centre Nat Rech Scient 3',6-substituierte indirubine und ihre biologischen anwendungen
EP2518139A1 (en) * 2011-04-27 2012-10-31 Universitätsklinikum Jena Use of indirubin derivatives for producing pluripotent stem cells

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541244A (ja) 1999-04-12 2002-12-03 ゲルハルト アイゼンブランド インジゴイドビスインドール誘導体
JP2007519713A (ja) 2004-01-27 2007-07-19 エニジェン カンパニー リミテッド ヒト癌細胞に対する抗癌性を有するインジルビン誘導体
JP2013518874A (ja) 2010-02-05 2013-05-23 エニジェン カンパニー．，リミテッド． 強力なサイクリン依存性キナーゼ阻害剤としてのインディルビン−３’−オキシム誘導体
US20160243077A1 (en) 2012-03-23 2016-08-25 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US20140275168A1 (en) 2013-03-14 2014-09-18 City Of Hope Indirubin derivatives, and uses thereof
JP2016514160A (ja) 2013-03-14 2016-05-19 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ ５−ブロモ−インジルビン
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cheng, Xinlai et al，"Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule"，Journal of Medicinal Chemistry，2017年，Vol.60(12)，p.4949-4962
D Marko1, S Schatzle1, A Friedel1, et al，Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells，British Journal of Cancer，2001年，Vol.84，p.283-289
Han, Sun-Young et al，"Effects of indirubin derivatives on the FLT3 activity and growth of acute myeloid leukemia cell lines"，Drug Development Research，2010年，Vol.71(4)，p.221-227
Nam, Sangkil; Scuto, Anna; Yang, Fan; Chen, Wen Yong; et al，"Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling"，Molecular Oncology，2012年，Vol.6(3)，p.276-283

Also Published As

Publication number Publication date
RU2020115581A (ru) 2021-12-02
CA3080900C (en) 2022-10-25
KR102247795B1 (ko) 2021-05-04
AU2018358582B2 (en) 2021-06-10
US20200270229A1 (en) 2020-08-27
EP3705474A1 (en) 2020-09-09
JP2021501208A (ja) 2021-01-14
RU2763346C2 (ru) 2021-12-28
KR20190049584A (ko) 2019-05-09
BR112020008499A2 (pt) 2020-10-20
CA3080900A1 (en) 2019-05-09
RU2020115581A3 (enExample) 2021-12-02
US11370779B2 (en) 2022-06-28
EP3705474A4 (en) 2021-06-09
MX2020004374A (es) 2020-11-11
KR102247795B9 (ko) 2023-04-12
CN111542513A (zh) 2020-08-14
PH12020550491A1 (en) 2021-01-11
WO2019088677A1 (ko) 2019-05-09
AU2018358582A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
JP7005779B2 (ja) 急性骨髄性白血病又は転移性乳癌の予防又は治療用薬剤学的組成物
DK2497772T3 (en) A compound for inhibiting mitotic progression
JP7431309B2 (ja) 血液悪性腫瘍患者の治療方法
MXPA04003853A (es) Tratamiento de la leucemia mieloide aguda con compuestos de indolinona.
SK12472002A3 (sk) 5-Alkylpyrido[2,3-d]pyrimidínové inhibítory tyrosínových kináz
CA2863673A1 (en) 2-amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as raf kinase inhibitors
HUE027534T2 (en) Notch pathway inhibitory compound
CN103596568A (zh) 治疗帕金森病的方法以及组合物
RS57144B1 (sr) Prolekovi kvinazolin amina kao inhibitori kinaze
JP2025503139A (ja) 固形腫瘍の治療のためのユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤
WO2019029629A1 (en) SUBSTITUTED PYRAZOLOPYRIMIDINES FOR USE AS KINASE INHIBITORS
WO2010096395A1 (en) Amides as kinase inhibitors
CN120302969A (zh) 可用作iap抑制剂的化合物和组合物
KR20210047850A (ko) 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물
CN109111439B (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
CN106467540A (zh) 蝶啶酮衍生物作为flt3抑制剂的应用
KR102682516B1 (ko) 퀴놀린 구조를 갖는 pan-kit 키나제 억제제 및 이의 용도
CN111116572B (zh) 噁二唑衍生物及其制备方法和用途
CN116589464B (zh) 嘧啶并环类化合物、其制备方法和应用
TWI759829B (zh) 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
WO2025162428A1 (en) Cyclic peptide compounds and compositions as ras inhibitors
CN109134433A (zh) 一种抑制rock的化合物及其应用
AU2014280932B2 (en) Compounds for inhibiting mitotic progression
HK1134672B (en) Compounds for inhibiting mitotic progression
HK1175777B (en) Compound for inhibiting mitotic progression

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220105

R150 Certificate of patent or registration of utility model

Ref document number: 7005779

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250